$4.2 Billion Overactive Bladder Treatment (OAB) Markets - Global Forecasts to 2027: Growing R&D Investments and the Launch of Novel Therapies in the Coming Years - ResearchAndMarkets.com

2022-12-05
Business Wire
DUBLIN--(BUSINESS WIRE)--The "Overactive Bladder Treatment (OAB) Market by Drug type ( Anticholinergic (Solifenacin, Oxybutynin, Tolterodine, Darifenacin), Mirabegron), Botox, Neuromodulation, Disease Type (Idopathic OAB and Neurogenic OAB) and Region - Global Forecasts to 2027" report has been added to ResearchAndMarkets.com's offering.
'Overactive Bladder Treatment (OAB) Market by Drug type ( Anticholinergic (Solifenacin, Oxybutynin, Tolterodine, Darifenacin), Mirabegron), Botox, Neuromodulation, Disease Type (Idopathic OAB and Neurogenic OAB) and Region - Global Forecasts to 2027'
The global overactive bladder treatment market is projected to reach USD 4.2 billion by 2027 from USD 3.5 billion in 2022, at a CAGR of 3.6%
Rising prevalence of overactive bladder across the globe coupled with rising awareness about treatment options available is driving the growth of the market. Additionally, use of neuromodulation techniques for the treatment of OAB is further expected to have a significant positive impact.
The adoption of novel treatments and the launch of new drugs for OAB treatment are also likely to support market growth in the coming years.
Mirabegron segment dominates the overactive bladder (OAB) treatment market in 2021.
Based on type, the overactive bladder treatment market is segmented into anticholinergics, mirabegron, BOTOX, neuromodulation, and other treatments. Mirabegron held a dominant share of the market in 2021, owing to the lesser side-effects associated with this drug compared to other drug classes available in the market. Furthermore, neuromodulation segment is expected to grow at faster pace owing to launch of new SNM & PTNS for OAB in market.
The idiopathic overactive bladder segment will witness the highest growth in overactive bladder treatment market during the forecast period.
Based on disease type, the overactive bladder treatment market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. The idiopathic overactive bladder segment accounted for a larger market share due to the higher prevalence of idiopathic overactive bladder disorders and increased use of drugs for the treatment.
North America held dominant share in 2021.
In 2021, North America accounted for the major share in the OAB treatment market. North America holds majority of the key market players leading to maturity of OAB treatment market in this region. Furthermore, favorable reimbursement policies in US is one of the leading factor projecting market growth in North America.
Competitive landscape
Market Dynamics
Market Drivers
Rising Prevalence of Overactive Bladder Syndrome
Rapidly Aging Population and Subsequent Rise in Incidence of Diseases Characterized by Oab
Development and Use of Innovative Intravesical Therapies
Growing R&D Investments and the Launch of Novel Therapies in the Coming Years
Market Restraints
Frequent Product Recalls
Increased Side-Effects of Anticholinergic Drugs
Market Opportunities
Novel Treatments, Robust Pipelines, and Patent Cliff of Certain Drugs
Market Challenges
Social Stigma and Lack of Awareness About OAB
Companies mentioned:
Granules India Limited
Laborie
For more information about this report visit https://www.researchandmarkets.com/r/2n1a4y
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。